Alpha Talon Investment Research

Alpha Talon Investment Research

Home
Notes
Power, Policy & Markets
Guides to Investing
Letters and Reflection
ATIR Portfolios
Asia Market
Industry Analysis
Good Quality High Dividend
Deep Value
IT
BioPharma Healthcare
Special Situation
M&A
Short Thesis
Archive
Newsletters
Leaderboard
About

Short Thesis

HOPE-3 Under the Microscope: Data, Framing, and Regulatory Reality
Why "Statistically Positive Data", Procedural FDA Alignment, and Approval Risk Remain Fundamentally Misaligned
 • AT Investment Research
Capricor Therapeutics (CAPR): HOPE-3 Isn’t the Turnaround the Market Priced It To Be
Why today’s “positive” data doesn’t change the regulatory math, and why my previous short selling thesis will hold
 • AT Investment Research
The Quantum Hangover: Shorting a Bubble That Was Never a Market
What’s Left After Hype, After the Crash, After the Fantasy?
 • AT Investment Research
U.S. Quantum Initiative (QBI): Who Actually Made the Cut?
IonQ’s in, Rigetti’s out, and the rest are chasing contracts around the edges.
 • AT Investment Research
[Subscriber Special] Capricor Therapeutics (CAPR): The Illusion of a Pipeline
A clinical-stage biotech with no cash flow, no credible pipeline, and rising dilution risk
 • AT Investment Research
Plastic Faith: The Rise and Unraveling of POP MART (HKEX: 9992)’s Cult Economy
Behind the glossy figurines and billion-dollar branding lies a slow-motion unwind — from narrative compounding to behavioral decay.
 • AT Investment Research
Rigetti’s Transparency: The Short Case Writes Itself (Subsequent Follow-up)
Unlike its quantum peers, RGTI’s plain disclosures make the bear thesis obvious — no sales, heavy dilution, and an overvalued stock.
 • AT Investment Research
Follow-up Mega Report: D-Wave is Collapsing in the Quantum Race
DARPA’s QBI snub, broken promises, and a roadmap buried in the past — why QBTS is fast becoming irrelevant in the modern quantum era.
 • AT Investment Research
Subsequent Followup: IonQ’s Bubble Gets Bigger With Every Headline!
A $23B bubble: IonQ’s soaring valuation rests on hype, dilution, and M&A spin—not real quantum progress.
 • AT Investment Research
Archer Aviation (ACHR): Our Short Case
Noise at the pad, certification risk, and unit economics that don’t add up.
 • AT Investment Research
Rigetti’s Q2 2025: Quantum "Breakthroughs", Financial Setbacks
Hype over chiplet milestones masks shrinking revenues, deepening losses, and accelerating shareholder dilution
 • AT Investment Research
Quantum Computing’s False Prophet: The $6B Short Case on D-Wave (QBTS)
A deep dive into flawed tech, broken financials, and why the numbers point to a 97% Collapse
 • AT Investment Research
© 2026 Alpha Talon Investment Research Limited · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture